-+ 0.00%
-+ 0.00%
-+ 0.00%

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B STUDY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH NSCLC

Reuters·12/17/2025 12:00:03

Please log in to view news